Pasithea Therapeutics (NASDAQ:KTTA) Posts Earnings Results

Pasithea Therapeutics (NASDAQ:KTTA) issued its earnings results on Monday. The company reported ($2.41) earnings per share for the quarter, Zacks reports.

Pasithea Therapeutics Stock Performance

Shares of Pasithea Therapeutics stock traded up $0.01 during midday trading on Monday, hitting $1.25. The company’s stock had a trading volume of 61,129 shares, compared to its average volume of 535,974. Pasithea Therapeutics has a 1-year low of $0.92 and a 1-year high of $9.25. The stock has a 50-day simple moving average of $1.70 and a 200-day simple moving average of $2.97.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.